Dyadic International, a renowned global biotechnology company, has recently achieved a significant milestone with the publication of their latest study in Nature Communications. The study’s groundbreaking findings showcase the efficacy of Dyadic’s C1 Monoclonal Antibody, which was produced using filamentous fungus, in providing protection against SARS-CoV-2. The results demonstrated its potential in hamster and nonhuman primate models, thereby offering promising advancements in the fight against the ongoing COVID-19 pandemic.
With their primary focus on developing innovative microbial protein production platforms, Dyadic International stands at the forefront of biotechnological advancements. The company’s diligent efforts have culminated in the groundbreaking publication of their study in Nature Communications, a highly respected and peer-reviewed international journal. This platform allows Dyadic’s commendable achievements to reach a wide audience, thereby enabling the scientific community and stakeholders to assess and appreciate the significance of their findings.
The manuscript
Comments